# Ata Post Acth Tumor Gc

> Recommend continuing glucocorticoid replacement until hypothalamic-pituitary-adrenal (HPA) axis recovery after surgical resection of ACTH-secreting pituitary tumors. Use when managing postoperative patients following ACTH-secreting tumor surgery to prevent adrenal insufficiency during HPA axis recovery.

- Skill: `dromlakhani/ata-post-acth-tumor-gc` (Agent Skill)
- Install (CLI): `npx skillmds add dromlakhani/ata-post-acth-tumor-gc`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/ata-post-acth-tumor-gc/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-08-19
- Page: https://skillmd.com/skills/dromlakhani/ata-post-acth-tumor-gc

---


# Continue glucocorticoid replacement until HPA axis recovery post-ACTH-secreting tumor surgery

## STEP 1 — Gather Information
Collect postoperative clinical status, surgical pathology confirming ACTH-secreting tumor, timing of surgery, assess for symptoms of adrenal insufficiency (fatigue, hypotension, hyponatremia), obtain morning cortisol level and consider ACTH stimulation test if cortisol equivocal.  
→ Proceed to evaluate HPA axis function.

## STEP 2 — Rule In / Rule Out
Rule in adrenal insufficiency if morning cortisol <5 µg/dL or subnormal peak cortisol <18.1 µg/dL after standard (250 µg) ACTH stimulation; rule out if morning cortisol ≥15 µg/dL and normal ACTH stim peak.  
→ Classify HPA axis recovery status.

## STEP 3 — Classify or Stratify
Stratify HPA axis recovery as none (AI present), partial (subnormal response), or full (normal cortisol dynamics).  
→ Decide on glucocorticoid management.

## STEP 4 — Decide
Continue glucocorticoid replacement (hydrocortisone 15–20 mg daily in divided doses) until full HPA axis recovery is confirmed; taper gradually once normal axis function demonstrated.  
→ Provide GC replacement plan.

## Clinical Guardrails / Mimics / Pitfalls
Do not stop glucocorticoids prematurely based solely on absence of symptoms; avoid over-replacement leading to iatrogenic Cushingoid features, hyperglycemia, or osteoporosis; consider stress dosing for intercurrent illness even if baseline axis appears recovering.

## Concrete Clinical Example
A 45-year-old woman with ACTH-secreting pituitary macroadenoma undergoes transsphenoidal resection; postoperative day 1 she receives hydrocortisone 20 mg daily. Morning cortisol on postoperative day 3 is 2 µg/dL. She continues hydrocortisone 15 mg AM/5 mg PM. At 3 months, morning cortisol is 12 µg/dL with subnormal ACTH stim peak (14 µg/dL); she continues GC replacement. At 6 months, morning cortisol 18 µg/dL and ACTH stim peak 22 µg/dL; glucocorticoids are tapered over 4 weeks and discontinued.

**Source:** Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118